Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment

Primary prostate cancer (PC) progresses to castration-resistant PC (CRPC) during androgen deprivation therapy (ADR) in early stages of prostate cancer. Thus, rather than blocking the androgen-related pathway further, docetaxel (DTX)-based therapy has become the most effective and standard first-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yingying, Duan, Hongxia, Zhao, Heming, Qi, Lingling, Liu, Yanhong, Zhang, Zheao, Liu, Chao, Chen, Liqing, Jin, Mingji, Guan, Youyan, Gao, Zhonggao, Huang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146571/
https://www.ncbi.nlm.nih.gov/pubmed/35631549
http://dx.doi.org/10.3390/pharmaceutics14050964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146571/
https://www.ncbi.nlm.nih.gov/pubmed/35631549
http://dx.doi.org/10.3390/pharmaceutics14050964

Ejemplares similares